See more : CITIC Limited (CTPCY) Income Statement Analysis – Financial Results
Complete financial analysis of Danimer Scientific, Inc. (DNMR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Danimer Scientific, Inc., a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
You may be interested
- Boston Omaha Corporation (BOMN) Income Statement Analysis – Financial Results
- UP GARAGE GROUP Co., Ltd. (7134.T) Income Statement Analysis – Financial Results
- IHS Holding Limited (IHS) Income Statement Analysis – Financial Results
- Promithian Global Ventures, Inc. (PGVI) Income Statement Analysis – Financial Results
- Holmes Place International Ltd (HLMS.TA) Income Statement Analysis – Financial Results
Danimer Scientific, Inc. (DNMR)
About Danimer Scientific, Inc.
Danimer Scientific, Inc., a performance polymer company, develops, produces, and provides bioplastic replacements for traditional petroleum-based plastics. It produces polyhydroxyalkanoate, a biodegradable plastic feedstock alternative used in a range of plastic applications, including films, straws, food containers, and other things under the Nodax brand name; polylactic acid-based resins for coating disposable paper cups; and other biopolymers. The company offers its products for biopolymers, including additives, aqueous coatings, fibers, filaments, films, thermoforming, and injection-molded articles. It also markets its products to consumer packaging brand owners, converters, and manufacturers in the plastics industry. Danimer Scientific, Inc. was founded in 2004 and is headquartered in Bainbridge, Georgia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 46.68M | 53.22M | 58.75M | 47.33M | 32.34M | 30.45M |
| Cost of Revenue | 73.64M | 63.63M | 57.87M | 35.88M | 21.24M | 19.21M |
| Gross Profit | -26.96M | -10.41M | 884.00K | 11.46M | 11.11M | 11.25M |
| Gross Profit Ratio | -57.75% | -19.57% | 1.50% | 24.21% | 34.34% | 36.92% |
| Research & Development | 29.24M | 31.94M | 20.27M | 7.85M | 5.48M | 5.14M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.26M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.00K |
| SG&A | 68.98M | 81.59M | 80.00M | 19.34M | 16.03M | 7.36M |
| Other Expenses | 434.00K | 723.00K | -44.00K | -31.00K | 277.00K | 0.00 |
| Operating Expenses | 98.66M | 113.53M | 100.27M | 27.19M | 21.51M | 8.11M |
| Cost & Expenses | 172.30M | 177.16M | 158.14M | 63.07M | 42.75M | 27.32M |
| Interest Income | 0.00 | 1.72M | 763.00K | 347.00K | 340.00K | 2.88M |
| Interest Expense | 0.00 | 112.25M | 763.00K | 2.43M | 3.48M | 0.00 |
| Depreciation & Amortization | 29.06M | 20.09M | 11.67M | 4.61M | 3.51M | 3.54M |
| EBITDA | -96.46M | -103.49M | -87.72M | -10.30M | -6.90M | 2.35M |
| EBITDA Ratio | -206.61% | -90.63% | -151.15% | -21.76% | -12.87% | 7.70% |
| Operating Income | -125.62M | -187.43M | -99.39M | -15.74M | -10.40M | -1.19M |
| Operating Income Ratio | -269.08% | -352.20% | -169.18% | -33.25% | -32.16% | -3.91% |
| Total Other Income/Expenses | -29.54M | 6.87M | 26.13M | 6.88M | -5.03M | -2.91M |
| Income Before Tax | -155.15M | -180.57M | -73.34M | -12.57M | -15.43M | 259.00K |
| Income Before Tax Ratio | -332.35% | -339.30% | -124.84% | -26.56% | -47.70% | 0.85% |
| Income Tax Expense | 319.00K | -810.00K | -13.23M | 2.40M | 4.09M | 51.00K |
| Net Income | -155.47M | -179.76M | -60.11M | -14.97M | -19.51M | 208.00K |
| Net Income Ratio | -333.03% | -337.78% | -102.31% | -31.62% | -60.33% | 0.68% |
| EPS | -1.52 | -1.78 | -0.65 | -0.18 | -0.77 | 0.07 |
| EPS Diluted | -1.52 | -1.78 | -0.65 | -0.18 | -0.77 | 0.07 |
| Weighted Avg Shares Out | 102.00M | 101.10M | 93.08M | 84.54M | 25.37M | 2.97M |
| Weighted Avg Shares Out (Dil) | 102.00M | 101.10M | 93.08M | 84.54M | 25.37M | 2.96M |
Danimer Scientific, Inc (DNMR) Q2 2024 Earnings Call Transcript
Danimer Scientific, Inc (NYSE:DNMR ) Q2 2024 Results Conference Call August 8, 2024 4:30 PM ET Company Participants Blake Chamblee - Director of Financial Reporting Stephen Croskrey - Chairman and Chief Executive Officer Mike Hajost - Chief Financial Officer Conference...
Danimer Scientific, Inc. (DNMR) Reports Q2 Loss, Lags Revenue Estimates
Danimer Scientific, Inc. (DNMR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.38 per share a year ago.
Danimer Scientific Announces Release Date for Second Quarter 2024 Results
BAINBRIDGE, Ga.--(BUSINESS WIRE)--Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”), a leading, next-generation bioplastics company focused on the development and production of biodegradable materials, announced today that the Company will release its second quarter 2024 financial results after the...
Danimer Scientific Completes Dividend Distribution of Warrants to Stockholders
BAINBRIDGE, Ga.--(BUSINESS WIRE)--Danimer Scientific, Inc. (NYSE: DNMR) (“Company” or “Danimer Scientific”), a leading next generation bioplastics company focused on the development and production of biodegradable materials, today announced the completion of a previously announced pro-rata dividend distribution of warrants (“Dividend...
Danimer Scientific Receives Continued Listing Standard Notice from NYSE
BAINBRIDGE, Ga.--(BUSINESS WIRE)--Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”), a leading, next-generation bioplastics company focused on the production of biodegradable materials, announced that it received a notice from the New York Stock Exchange (“NYSE”) on May 21, 2024,...
Danimer Scientific Announces Steve Croskrey Retirement and Related Changes to the Company's Board of Directors
BAINBRIDGE, Ga.--(BUSINESS WIRE)--Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”), a leading next generation bioplastics company focused on the development and production of biodegradable materials, announced today that Stephen E. Croskrey has informed the Board of Directors that he...
Danimer Scientific, Inc. (DNMR) Q1 2024 Earnings Call Transcript
Danimer Scientific, Inc. (NYSE:DNMR ) Q1 2024 Results Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Blake Chamblee - Director of Financial Reporting Stephen Croskrey - Chairman and Chief Executive Officer Mike Hajost - Chief Financial Officer...
Danimer Scientific Reveals New Branding and New Applications Based on PHA During NPE 2024
BAINBRIDGE, Ga.--(BUSINESS WIRE)---- $DNMR--Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”), a leading next-generation bioplastics company focused on the development and production of PHA biopolymers, is unveiling new commercial applications and branding during NPE 2024, North America's largest plastics...
Danimer Scientific Announces Proposed Pro-Rata Distribution of Warrants to Purchase Common Stock
BAINBRIDGE, Ga.--(BUSINESS WIRE)--Danimer Scientific, Inc. (NYSE: DNMR) (“Company” or “Danimer Scientific”), a leading next generation bioplastics company focused on the development and production of biodegradable materials, today announced a proposed pro-rata dividend distribution of warrants (“Dividend Warrants”) to holders of...
Will Danimer Scientific, Inc. (DNMR) Report Negative Q1 Earnings? What You Should Know
Danimer Scientific (DNMR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Source: https://incomestatements.info
Category: Stock Reports